Evidence map›Paper›PMID 20585642›Full record

ArticlePloS one2010

To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling.

Bruce Y Lee, Sarah M McGlone, Rachel R Bailey, Ann E Wiringa, Shanta M Zimmer, Kenneth J Smith, Richard K Zimmerman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Molecular Testing for Acute Respiratory Tract Infections: Clinical and Diagnostic Recommendations From the IDSA's Diagnostics Committee.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  12. Article
  13. Article
  14. Cost-Effective Respiratory Virus Testing.Journal of clinical microbiology · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bruce Y LeeDepartment of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. BYL1@pitt.edu
Sarah M McGlone
Rachel R Bailey
Ann E Wiringa
Shanta M Zimmer
Kenneth J Smith
Richard K Zimmerman
University of Pittsburgh · US

Funding

Training, Outreach & Diversity ComponentU54GM088491 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VAN PANHUIS, WILLEM GIJSBERT · 2009 to 2018
$16.7M
Decision Making in BiosurveillanceR01LM009132 · NLM · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WAGNER, MICHAEL MATTHEW · 2008 to 2011
$1.9M
NIGMS NIH HHS 1U54GM088491-0109NLM NIH HHS 5R01LM009132-02NLM NIH HHS R01 LM009132
6 · The paper itself

Abstract

backgroundDue to the unpredictable burden of pandemic influenza, the best strategy to manage testing, such as rapid or polymerase chain reaction (PCR), and antiviral medications for patients who present with influenza-like illness (ILI) is unknown. METHODOLOGY/PRINCIPAL

findingsWe developed a set of computer simulation models to evaluate the potential economic value of seven strategies under seasonal and pandemic influenza conditions: (1) using clinical judgment alone to guide antiviral use, (2) using PCR to determine whether to initiate antivirals, (3) using a rapid (point-of-care) test to determine antiviral use, (4) using a combination of a point-of-care test and clinical judgment, (5) using clinical judgment and confirming the diagnosis with PCR testing, (6) treating all with antivirals, and (7) not treating anyone with antivirals. For healthy younger adults (<65 years old) presenting with ILI in a seasonal influenza scenario, strategies were only cost-effective from the societal perspective. Clinical judgment, followed by PCR and point-of-care testing, was found to be cost-effective given a high influenza probability. Doubling hospitalization risk and mortality (representing either higher risk individuals or more virulent strains) made using clinical judgment to guide antiviral decision-making cost-effective, as well as PCR testing, point-of-care testing, and point-of-care testing used in conjunction with clinical judgment. For older adults (> or = 65 years old), in both seasonal and pandemic influenza scenarios, employing PCR was the most cost-effective option, with the closest competitor being clinical judgment (when judgment accuracy > or = 50%). Point-of-care testing plus clinical judgment was cost-effective with higher probabilities of influenza. Treating all symptomatic ILI patients with antivirals was cost-effective only in older adults. CONCLUSIONS/SIGNIFICANCE: Our study delineated the conditions under which different testing and antiviral strategies may be cost-effective, showing the importance of accuracy, as seen with PCR or highly sensitive clinical judgment.

Indexed as

Computer SimulationModels, EconomicAntiviral AgentsHumansInfluenza, HumanPoint-of-Care SystemsPolymerase Chain ReactionAntiviral Agents

Identifiers

PMID20585642
PMCPMC2890406
OpenAlexW2015946045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.